Cargando…

Myo-Inositol in the Treatment of Teenagers Affected by PCOS

Objective. To compare the effectiveness of myo-inositol (MI) and oral contraceptive pills (OCPs) in monotherapy and MI in combination with OCPs in the treatment of teenagers affected by polycystic ovary syndrome (PCOS). Methods. 61 adolescent girls aged 13–19 years, with PCOS, were involved in the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pkhaladze, Lali, Barbakadze, Ludmila, Kvashilava, Nana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007307/
https://www.ncbi.nlm.nih.gov/pubmed/27635134
http://dx.doi.org/10.1155/2016/1473612
_version_ 1782451183598698496
author Pkhaladze, Lali
Barbakadze, Ludmila
Kvashilava, Nana
author_facet Pkhaladze, Lali
Barbakadze, Ludmila
Kvashilava, Nana
author_sort Pkhaladze, Lali
collection PubMed
description Objective. To compare the effectiveness of myo-inositol (MI) and oral contraceptive pills (OCPs) in monotherapy and MI in combination with OCPs in the treatment of teenagers affected by polycystic ovary syndrome (PCOS). Methods. 61 adolescent girls aged 13–19 years, with PCOS, were involved in the prospective, open-label study. Patients were randomized into three groups: I group, 20 patients receiving drospirenone 3 mg/ethinyl estradiol 30 μg; II group, 20 patients receiving 4 g myo-inositol plus 400 mg folic acid; III group, 21 patients receiving both medications. Results. After receiving MI significant reduction in weight, BMI, glucose, C-peptide, insulin, HOMA-IR, FT, and LH was detected. The levels of SHBG, TT, FAI, DHEA-S, and AMH did not change statistically significantly. After receiving OCPs weight and BMI slightly increased, but metabolic parameters did not change. Combination of MI and OCPs did not change weight and BMI, but reduction in C-peptide, insulin, and HOMA-IR was detected. TT, FT, FAI, DHEA-S, LH, and AMH levels decreased and SHBG increased. Conclusions. Administration of MI is a safe and effective method to prevent and correct metabolic disorders in teenagers affected by PCOS. With combination of MI and OCPs antiandrogenic effects are enhanced, negative impact of OCPs on weight gain is balanced, and metabolic profile is improved.
format Online
Article
Text
id pubmed-5007307
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-50073072016-09-15 Myo-Inositol in the Treatment of Teenagers Affected by PCOS Pkhaladze, Lali Barbakadze, Ludmila Kvashilava, Nana Int J Endocrinol Clinical Study Objective. To compare the effectiveness of myo-inositol (MI) and oral contraceptive pills (OCPs) in monotherapy and MI in combination with OCPs in the treatment of teenagers affected by polycystic ovary syndrome (PCOS). Methods. 61 adolescent girls aged 13–19 years, with PCOS, were involved in the prospective, open-label study. Patients were randomized into three groups: I group, 20 patients receiving drospirenone 3 mg/ethinyl estradiol 30 μg; II group, 20 patients receiving 4 g myo-inositol plus 400 mg folic acid; III group, 21 patients receiving both medications. Results. After receiving MI significant reduction in weight, BMI, glucose, C-peptide, insulin, HOMA-IR, FT, and LH was detected. The levels of SHBG, TT, FAI, DHEA-S, and AMH did not change statistically significantly. After receiving OCPs weight and BMI slightly increased, but metabolic parameters did not change. Combination of MI and OCPs did not change weight and BMI, but reduction in C-peptide, insulin, and HOMA-IR was detected. TT, FT, FAI, DHEA-S, LH, and AMH levels decreased and SHBG increased. Conclusions. Administration of MI is a safe and effective method to prevent and correct metabolic disorders in teenagers affected by PCOS. With combination of MI and OCPs antiandrogenic effects are enhanced, negative impact of OCPs on weight gain is balanced, and metabolic profile is improved. Hindawi Publishing Corporation 2016 2016-08-18 /pmc/articles/PMC5007307/ /pubmed/27635134 http://dx.doi.org/10.1155/2016/1473612 Text en Copyright © 2016 Lali Pkhaladze et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Pkhaladze, Lali
Barbakadze, Ludmila
Kvashilava, Nana
Myo-Inositol in the Treatment of Teenagers Affected by PCOS
title Myo-Inositol in the Treatment of Teenagers Affected by PCOS
title_full Myo-Inositol in the Treatment of Teenagers Affected by PCOS
title_fullStr Myo-Inositol in the Treatment of Teenagers Affected by PCOS
title_full_unstemmed Myo-Inositol in the Treatment of Teenagers Affected by PCOS
title_short Myo-Inositol in the Treatment of Teenagers Affected by PCOS
title_sort myo-inositol in the treatment of teenagers affected by pcos
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007307/
https://www.ncbi.nlm.nih.gov/pubmed/27635134
http://dx.doi.org/10.1155/2016/1473612
work_keys_str_mv AT pkhaladzelali myoinositolinthetreatmentofteenagersaffectedbypcos
AT barbakadzeludmila myoinositolinthetreatmentofteenagersaffectedbypcos
AT kvashilavanana myoinositolinthetreatmentofteenagersaffectedbypcos